Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer
- PDF / 1,612,032 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 113 Downloads / 228 Views
ORIGINAL ARTICLE – TRANSLATIONAL RESEARCH
Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer Gu-Wei Ji, MD, PhD1,2,3, Ke Wang, MD, PhD1,2,3, Yong-Xiang Xia, MD, PhD1,2,3, Jin-Song Wang, MD4, Xue-Hao Wang, MD1,2,3 , and Xiang-Cheng Li, MD, PhD1,2,3 1
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, People’s Republic of China; 3 NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing, People’s Republic of China; 4Department of Pathology, Nanjing First Hospital, Nanjing, People’s Republic of China 2
ABSTRACT Background. Improved methods are needed to predict outcomes in biliary tract cancers (BTCs). We aimed to build an immune-related signature and establish holistic models using machine learning. Methods. Samples were from 305 BTC patients treated with curative-intent resection, divided into derivation and validation cohorts in a two-to-one ratio. Spatial resolution of T cell infiltration and PD-1/PD-L1 expression was assessed by immunohistochemistry. An immune signature was constructed using classification and regression tree. Machine learning was applied to develop prediction models for disease-specific survival (DSS) and recurrence-free survival (RFS). Results. The immune signature composed of CD3?, CD8?, and PD-1? cell densities and PD-L1 expression within tumor epithelium significantly stratified patients into three clusters, with median DSS varying from 11.7 to 80.8 months and median RFS varying from 6.2 to 62.0 months. Gradient boosting machines (GBM)
Electronic supplementary material The online version of this article (https://doi.org/10.1245/s10434-020-09374-w) contains supplementary material, which is available to authorized users. Ó Society of Surgical Oncology 2020 First Received: 28 August 2020 Accepted: 27 October 2020 X.-H. Wang, MD e-mail: [email protected] X.-C. Li, MD, PhD e-mail: [email protected]
outperformed rival machine-learning algorithms and selected the same 11 covariates for DSS and RFS prediction: immune signature, tumor site, age, bilirubin, albumin, carcinoembryonic antigen, cancer antigen 19-9, tumor size, tumor differentiation, resection margin, and nodal metastasis. The clinical-immune GBM models accurately predicted DSS and RFS, with respective concordance index of 0.776–0.816 and 0.741–0.781. GBM models showed significantly improved performance compared with tumornode-metastasis staging system. Conclusions. The immune signature promises to stratify prognosis and allocate treatment in resected BTC. The clinical-immune GBM models accurately predict recurrence and death from BTC following surgery.
Biliary tract cancers (BTCs) are aggressive malignancies arising from the epithelial lining of intra- and extrahepatic bile ducts as well as gallbladder and carry a poor prognosis.1 Surgical resection offers a chance for cur
Data Loading...
